Fig. 1. Neutralizing monoclonal antibodies: identification, selection and production.
The neutralizing monoclonal antibodies (mAbs) given emergency use authorization for treatment of COVID-19 were derived from either convalescent patients or humanized mice exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens. However, mAbs can be generated by multiple methods, including from vaccinated individuals (not depicted here). The pathways of mAb generation depicted here converge in the process of selection and production. RBD, receptor-binding domain.